Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines현재 사용 가능한 COVID-19 백신에 저항할 가능성이 있는 새로 분류된 관심 변종인 SARS-CoV-2 Mu에 대처하기 위한 전략Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration adopted approach B.1 lineage B.1.621 BNT161b2 booster dose Characteristics coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine COVID-19 vaccine development Evidence exacerbated Genetic genomic Genomic surveillance global mass vaccination Health implementation infections Intervention Lineage mass vaccination Mu variant mutations Neutralizing non-pharmaceutical interventions (NPIs) NPIs potential risk public health measure public health measures Recombination reported required respiratory restrict SARS-CoV-2 SARS-CoV-2 B.1.621 SARS-CoV-2 virus sera shown Strains Strategy sub-lineage B.1.621.1 Surveillance survivor the SARS-CoV-2 virus therapeutic threat vaccination Vaccine vaccine breakthrough. Vaccine development variant variants [DOI] 10.1080/21645515.2022.2027197 PMC 바로가기 [Article Type] Article
Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse급성 재발의 징후를 나타내는 다발성 경화증을 가진 리툭시맙으로 치료받은 사람에서 BBIBP-CorV COVID-19 백신 접종 후 항-NMDA 수용체 항체 검출Article Published on 2022-12-312022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, 진단, [키워드] added administration Anti-N-methyl-D-aspartate receptor Anti-N-Methyl-d-Aspartate receptor antibodies anti-NMDAR antibodies antibody ataxic Autoimmune Autoimmune encephalitis Babinski sign BBIBP-CorV benefit Case report clinician corticosteroid pulse COVID-19 COVID-19 vaccination CSF analysis detection early diagnosis Encephalitis initiated manifestation MRI multiple sclerosis multiple sclerosis. Neurological symptom NMDAR Patient performed Physical examination plaques positive presenting receiving receptor second dose serum Sinopharm Symptoms tested therapy Vaccines worsening [DOI] 10.1080/21645515.2022.2033540 PMC 바로가기 [Article Type] Article
A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & JohnsonSARS-CoV-2 백신에 대한 포괄적인 검토: Pfizer, Moderna & Johnson & JohnsonReview Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] Adenovirus administration age approval clinical clinical trial clinical trials coronavirus coronavirus. COVID-19 COVID-19 vaccine COVID-19 vaccines effective Efficacy General population group Johnson Johnson & Johnson Johnson & large cohort mechanism moderate Moderna mRNA vaccines Novel coronavirus ongoing trial ongoing trials outbreak pandemic participant Pfizer Safety SARS-CoV-2 SARS-CoV-2 coronavirus SARS-COV-2 infection shown Side effects Spike protein symptomatic SARS-CoV-2 infection tested the SARS-CoV-2 the spike protein the United State Trial United States Vaccinations Vaccine vaccine administration variant [DOI] 10.1080/21645515.2021.2002083 PMC 바로가기 [Article Type] Review
A case-case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variantsDelta 및 Omicron 변종에 감염된 백신 접종자의 폐렴 및 바이러스 부하 예방에 대한 중국산 COVID-19 백신의 1차 및 추가 접종 효과에 대한 사례 연구Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] administration age analysed association booster booster dose booster immunization calculate case study case-case study COVID-19 COVID-19 outbreak COVID-19 pneumonia COVID-19 vaccine Ct value Ct values Delta determine eligible evaluated immunization Infection infections less Logistic regression no difference no differences Odds ratio Odds ratios omicron pace Pneumonia real-world study. recipient reduced reduction SARS-CoV-2 viral load vaccination Vaccination Status variant Viral load [DOI] 10.1080/22221751.2022.2103455 PMC 바로가기 [Article Type] Article
Influenza and pneumococcal vaccination and COVID-19 in kidney transplant patientsResearch article Published on 2022-12-012022-10-05 Journal: Transplant immunology [Category] 변종, 진단, 치료제, [키워드] addition administration benefit Clinical course control group COVID COVID-19 COVID-19 infection disease Donor dysfunction examined follow-up time group Hospital stay Hospitalization increased the risk Influenza Influenza and pneumoccal vaccine intensive care kidney transplant kidney transplant recipient lack Logistic regression analysis median multivariate need for dialysis no significant difference observation outcome pandemic Patient pneumococcal positive recipient reduce Result risk of COVID-19 rRT-PCR test significantly higher the disease the patient vaccination vaccination rate Vaccine Vaccines with COVID-19 [DOI] 10.1016/j.trim.2022.101693 [Article Type] Research article
An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variantsSARS-CoV-2 오미크론 변이체에 감염된 중국 참가자의 VV116에 대한 공개, 전향적 코호트 연구Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] adjusted administration adverse event adverse events anti-SARS-CoV-2 antiviral drug baseline characteristics Chinese Cohort cohort study collected conducted control group COVID-19 Cox regression analysis effective Effectiveness Efficacy enrolled evaluate first positive Follow-up Hospitalized infected with SARS-CoV-2 Infection Intervention median time no significant difference omicron Omicron variant participant Patient preclinical studies predominant Prevalence prospective cohort study receive regression analysis reported resolved robust Safe Serious Adverse Event Serious Adverse Events standard treatment Symptom symptomatic treatment group variant variant of SARS-CoV-2 Viral load Viral load. viral shedding VV116 with COVID-19 [DOI] 10.1080/22221751.2022.2078230 PMC 바로가기 [Article Type] Article
Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysisArticle Published on 2022-12-012022-11-15 Journal: Drug Delivery [Category] COVID19(2023년), SARS, 치료제, [키워드] addition administration Analysis Antiviral antiviral activity Calu-3 Cell characterized Concentration COVID-19 cytotoxicity Favipiravir in vitro indicated Influenza virus Inhaled inhaled formulation inhibitor investigated lung lung epithelial cell lung tissue Lungs media Patient patients with COVID-19 PBS phosphate buffer profile pulmonary RdRP real time required respiratory. RNA-dependent RNA polymerase SARS-CoV-2 stability target Toxicity treat Treatment VERO-E6 viability were infected [DOI] 10.1080/10717544.2022.2118398 PMC 바로가기
Evaluation of response to different COVID-19 vaccines in vaccinated healthcare workers in a single center in IranArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 진단, [키워드] adenoviral-vectored vaccine Administered administration age anti-SARS-CoV-2 Anti-spike anti-spike antibody antibody Antibody Response average blood sample calculated center coronavirus disease Covaxin COVID-19 COVID-19 infection COVID-19 vaccine Cutoff ELISA evaluated Frequency healthcare worker individual Iran men Neutralizing antibodies neutralizing antibody neutralizing antibody. outcome Oxford/AstraZeneca pandemic participant participated positive proportion second dose significantly higher single center Sinopharm Sputnik V vaccination Vaccine Vaccines [DOI] 10.1002/jmv.28029 PMC 바로가기
A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants비강 오미크론 백신 부스터는 새로운 SARS-CoV-2 변이체에 대한 강력한 중화 항체 반응을 이끌어냅니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] absence adjuvants administration antibody Antibody Response boost booster Bronchoalveolar lavage caused clinical trial composed COVID-19 COVID-19 pandemic current deaths delta variant described disease severity domain dose effective Elevation elicit evidenced FIVE fused human infection human infections humans IgA Immunity immunogen intranasal leads mice MOST mucosal nasal nasal protein vaccine booster Neutralizing activity neutralizing antibody Neutralizing antibody response omicron Omicron variant omicron variant. Protein Receptor binding domain reduce respiratory SARS-CoV-2 SARS-CoV-2 nucleoprotein SARS-CoV-2 spike SARS-CoV-2 transmission SARS-CoV-2 variant severity significantly single dose suggested the antibody response the disease vaccination Vaccine virus infection wild-type [DOI] 10.1080/22221751.2022.2053365 PMC 바로가기 [Article Type] Article
Immunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shieldingArticle Published on 2022-12-012022-11-15 Journal: Current opinion in allergy and clinical immunology [Category] 진단, [키워드] administration Anxiety assessment collected Concentration coronavirus disease COVID-19 greater high risk IgG IgG level immunodeficient patient Immunoglobulin immunoglobulin replacement therapy In-hospital Infection intravenous Intravenous immunoglobulin IVIG Laboratory Measures mitigate outcome Patient receiving recent reported risk severe coronavirus disease shielding subcutaneously Subjective transitioned [DOI] 10.1097/ACI.0000000000000864 PMC 바로가기